TGFB1 and pulmonary fibrosis: This inhibitor is used commercially in patients who develop idiopathic pulmonary fibrosis and acts on signaling pathways triggered by TNF-α and TGF-β, such as SMAD and MAPK signaling pathway proteins [52].